The results of this study demonstrate that MTVcsc from a single pretreatment 18F-FDG PET/CT can predict whether the breast cancer patient would respond to NAC and experience a relapse after completion of treatment, especially in HER2-positive and TN subtypes. Here, ERBB2 is linked to breast cancer.